oral semaglutide structure | C187H291N45O59 | CID 56843331 The Quest for Oral GLP-1s

PlexusDx emphasizes precision wellness: understanding your baseline health markers, family history, and genetic predispositions in GLP-1 and appetite-regulation pathways can support a more informed conversation with your provider about whether semaglutide is right for you

Results No clinically relevant effects on the exposure were seen for sex, age, race, ethnicity, renal function, or injection site used, and semaglutide exposure was stable over time

Studies comparing semaglutide users to matched controls show that even at similar weight loss levels, semaglutide recipients exhibit greater improvements in inflammatory markers

Many patients identify specific food triggers during active disease, but dietary restrictions should not be overly restrictive during remission, as this may compromise nutritional status

The GLP-1 component suppresses appetite, slows gastric emptying, and improves insulin sensitivity